ReviewAnnals of translational medicine2022
Emerging therapies for non-small cell lung cancer harboring EGFR exon 20 insertion mutations: narrative review.
Review in Annals of translational medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Therapeutic Advances in Non-Small Cell Lung Cancer HarboringInternational journal of molecular sciences · 2026Review
- Analysis of the efficacy and influencing factors of double-dose furmonertinib for advanced EGFR ex20ins non-small cell lung cancer.Journal of translational medicine · 2025Article
- A Comprehensive Review of Advances in Molecular Mechanisms and Targeted Therapies for the Specific Type of Cystic Lung Cancer.OncoTargets and therapy · 2025Review
- New advances in the treatment of EGFR exon20ins mutant advanced NSCLC.American journal of cancer research · 2025Review
- Evolving treatment strategies for EGFRex20ins-mutated NSCLC: a comprehensive review of Amivantamab's role and future directions.Ecancermedicalscience · 2025Review
- Current status and breakthroughs in treating advanced non-small cell lung cancer with EGFR exon 20 insertion mutations.Frontiers in immunology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objective: Epidermal growth factor receptor ( Methods: Searches were conducted in PubMed and supplemented with recent conference proceedings in November 30th, 2021. Key Content and Findings: Several novel emerging therapies showed favorable safety profile and promising anti-tumor activity in NSCLC patients with EGFR ex20ins in recent several clinical trials. Conclusions: There is still room for improvement in the treatment results of NSCLC harboring EGFR ex20ins. Future research should focus on the molecular heterogeneity in the size and location of distinct EGFR ex20ins, the mechanisms of acquired resistance to novel EGFR inhibitors, effective treatment that have good central nervous system penetrance, and the potential role of combination strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.